An overview of various treatment opportunities under study that are looking at using novel techniques to help personalize treatment for patients with bile duct cancers.
R. Kate Kelley, MD, University of California-San Francisco
Advertisement
Articles by R. Kate Kelley, MD, University of California-San Francisco
Considerations for treating appropriate patients with advanced cholangiocarcinoma with an IDH inhibitor.
Advertisement
Latest Updated Articles
Cholangiocarcinoma: Potential Therapies Under InvestigationPublished: April 26th 2021 | Updated:
IDH Targeting in Advanced CholangiocarcinomaPublished: April 26th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5